Press Releases

Press Releases

September 3, 2019
SOUTH SAN FRANCISCO, Calif. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at the Morgan
August 7, 2019
ALLO-501 Phase 1 ALPHA Trial in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma ( NHL ) Advances with Five Clinical Trial Sites Open Investigational New Drug (IND) Application Cleared by the U.S. Food & Drug Administration ( FDA ) for ALLO-715 Targeting BCMA for the Treatment of Patients
May 29, 2019
SOUTH SAN FRANCISCO, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at three investor
May 7, 2019
Initiated ALLO-501 Phase 1 ALPHA Trial in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma ( NHL ) Investigational New Drug (IND) Application Submitted to the U.S. Food & Drug Administration ( FDA ) for ALLO-715 Targeting BCMA for the Treatment of Patients with Relapsed/Refractory Multiple
May 1, 2019
Newly Appointed Members Include Robert Abraham, Ph.D., Malcolm K. Brenner, M.D., Ph.D., Stephen J. Forman, M.D., and Wendell Lim, Ph.D. SOUTH SAN FRANCISCO, Calif. , May 01, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the
Displaying 1 - 10 of 18
Print Page
E-mail Alerts
RSS
Investor Contacts